Cell line · CVCL_0326
Papers156
1 to 20 of 156
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Morpholino-mediated splice switching of NELFE suppresses hepatocellular carcinoma cell phenotypes in vitro and in vivo. | Mol Ther Nucleic Acids | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A scalable, high-throughput glue perturbation screening platform for molecular glue discovery. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| RBM25 Drives Hepatocellular Carcinoma Progression by Stabilizing YAP Through Regulating Oncogenic Splicing-switch of MYPT1. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Bioactive Properties of Achillea biserrata M.Bieb. Extracts: Phytochemical Analysis, Antioxidant Activity, Target Enzyme Inhibition, and Cytotoxic Effects. | Chem Biodivers | 2026 | Its Methods give the RRID and name the line | PubMed | |
| RNF180 loss stabilizes BCAS4 to enhance PD-L1 expression and immune evasion in hepatocellular carcinoma. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Epigenetic priming and locus-specific demethylation enhance cell-death susceptibility in liver cancer. | Mol Cells | 2026 | Its Methods give the RRID and name the line | PubMed | |
| FKBP52 dictates the dual role of p53 in hepatocellular carcinoma: Mutation-specific prognostic stratification and therapeutic implications. | J Biol Chem | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Mechanosensors Collaborate to Regulate DNA Damage Repair in Hepatocellular Carcinoma. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Gene expression adaptation of metastases to their host tissue. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeted antibody-drug conjugates for rhabdomyosarcoma and other FGFR4-expressing cancers. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Epigenetic silencing of the liver-specific lncRNA LUNAR promotes liver cancer progression via NOTCH activation. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A Serum lncRNA Signature Determines Oncogenic YAP Activity in Cancer Patients. | Int J Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Gut Pathobionts Translocate into the Liver and Reshape Intrahepatic Microbiome to Facilitate Hepatocellular Carcinoma. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Salmonella vector creates de novo parvovirus that reduces solid tumors and forms antitumor immune memory. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| MAPRE2 is associated with macrophage-enriched innate immune dysregulation and malignant phenotypes in hepatocellular carcinoma. | Front Immunol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CENPA as a Genome Stability-Associated Biomarker in Hepatocellular Carcinoma: Multiomics Analysis and Experimental Validation. | Hum Mutat | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Functional genomic analysis reveals HAVCR1 as the key regulator of 5q33.3 locus linked to hyperlipidemia. | HGG Adv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Master Regulator SMC1A, Stabilized by N6-Methyladenosine Reader IGF2BP1, Promotes HCC Progression Through Facilitating Enhancer-Promoter Interaction of Nestin. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Subtype-dependent PD-L1 stability and immune context shape immunotherapy response in hepatocellular carcinoma. | Front Immunol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Dual Specificity Phosphatase 4 Enhances Immunotherapy Response by Inhibiting TGF-β1 Secretion in Hepatocellular Carcinoma. | Cancers (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0326/papers